Rogne Bioscience, Inc.
Biotechnology - , ,
Rogne Bioscience, Inc. Employees
Rogne Bioscience, Inc. Details
The company wound down all its research and development activities at the end of 2015, and dissolved the corporation in May 2016. The intellectual property relating to the Rogne program has been transferred to Oxford's technology licensing organization, Oxford University Innovation.Rogne Bioscience is an early stage start-up developing a first-in-class, anti-inflammatory human peptide as a topically applied treatment for psoriasis.Rogne's lead molecule is a potent, naturally-occurring peptide that acts as the body's own "off-switch" in inflammation. Our peptide reduces IL-23, the key inflammatory cytokine in psoriasis, and will offer a superior topical therapy option with equivalent efficacy to injected biologics but without side effects to the 6 million mild-to-moderate U.S. patients who can spend up to $1500/yr for branded topicals.For more information, contact us at info@rognebioscience.com
